Maruho Co.

Closed portfolio snapshot

According to ClinicalTrials.gov-derived indexes, Maruho Co. sits in the top decile of US sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count).

10 total trials none currently recruiting 10 completed top decile by trial count

Maruho Co.: 10 sponsored US clinical trials, none currently recruiting.

Maruho Co. sponsors 10 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 10 completed. 5 of these trials are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Acne Vulgaris, with 1 trials.

Top-decile sponsor footprint

Maruho Co. ranks in the top decile of sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

A 90/100

10 of 10 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (100.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Indexed trials (enrollment closed)

10 total, page 1 of 1

COMPLETED Phase 3

A Study to Evaluate the Safety and Efficacy of CLS006 Versus Vehicle in Subjects 2 Years of Age or Older With Cutaneous Common Warts

NCT03259620
COMPLETED Phase 3

A Phase 3 Study to Evaluate the Efficacy and Safety of CLS006 Versus Vehicle in Subjects 2 Years of Age or Older With Cutaneous Common Warts

NCT02971891
COMPLETED Phase 3

Study to Evaluate the Safety and Efficacy of a Once-Daily CLS001 Topical Gel Versus Vehicle

NCT02547441
COMPLETED Phase 3

Study to Evaluate the Long-term Safety of a Once-Daily Omiganan Topical Gel

NCT02576847
COMPLETED Phase 2

A Study to Evaluate the Safety and Efficacy of Omiganan (CLS001) Topical Gel Versus Vehicle in Female Subjects With Moderate to Severe Acne Vulgaris

NCT02571998
COMPLETED Phase 3

Study to Evaluate the Safety and Efficacy of a Once-Daily CLS001 Topical Gel Versus Vehicle

NCT02576860
COMPLETED Phase 2

Safety and Efficacy Study of CLS001Topical Gel Compared to Vehicle in Subjects With Inflammatory Acne Vulgaris

NCT02066545
COMPLETED Phase 1

A 21 Day Pharmacokinetics Study in Papulopustular Rosacea

NCT02028286
COMPLETED Phase 2

A Twelve Week Safety and Efficacy Study in Rosacea

NCT01784133
COMPLETED Phase 2

Study to Investigate the Efficacy and the Safety of M518101 in Plaque Psoriasis Patients

NCT01301157

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 4
Phase 3 5

Therapeutic Areas

Acne Vulgaris 1
Rosacea 1
Papulopustular Rosacea 1

How the Maruho Co. archive is shaped

10 indexed studies, none listed as recruiting (0% open); 10 completed (100%).

Phase mix: 5 late (III/IV) vs 5 early (I/II) (balanced across stages).

Top condition: Acne Vulgaris (1 trial), 2 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Maruho Co.: archived-pipeline peers nationwide

Peers matched on 10 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Maruho Co. sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%10%20%30%40% Total trials Recruiting share Maruho Co.Adamas PharmaceuticalsAdverum BiotechnologiesAevi Genomic Medicine, LLC, a Cerecor companyAgouron Pharmaceuticals10xBio22nd Century Group23andMe3-C Institute for Social Development
Maruho Co. sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Maruho Co. sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 10 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Maruho Co. page

10 registered trials is a research-attention snapshot, not an endorsement of Maruho Co. or any single study.

  • None of Maruho Co.'s trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Acne Vulgaris is the condition Maruho Co. studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Acne Vulgaris trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Maruho Co. pipeline card: 10 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.